Obesity is the result of genetic predisposition and environmental factors that confer an imbalance between energy intake and energy expenditure ([@B1]). Resulting energy excess is stored as triglycerides in white adipose tissue (WAT). Adult obesity is typically characterized by adipocyte hypertrophy when triglyceride synthesis exceeds breakdown (lipolysis). However, a concomitant adipocyte hyperplasia may also occur as a result of increased recruitment and differentiation of precursor cells (adipogenesis) ([@B2],[@B3]).

In addition to its role in energy storage, WAT is also a highly active metabolic and endocrine organ that regulates energy homeostasis by secreting a variety of adipokines ([@B4]). These factors may act at local (auto/paracrine) or systemic (endocrine) levels and enable WAT to modulate its own metabolic activities or that of other tissues. So, excess or deficiency of adipose tissue may generate metabolic disorders such as liver steatosis, insulin resistance, type 2 diabetes, and cardiovascular diseases.

The use of well-characterized preadipocyte cell lines, 3T3-L1 or 3T3-F442A, allowed us to draw a network of transcription factors regulating differentiation of fibroblast-like preadipocytes to lipid-loaded adipocytes ([@B5],[@B6]). Peroxisome proliferator-activated receptor γ and CCAAT/enhancer-binding proteins emerged as master regulators of the transcriptional cascade that drives adipogenesis ([@B7],[@B8]). Expression and activity of these transcriptional factors are controlled by various upstream stimuli (hormonal, paracrine, or nutritional), leading to the regulation of adipocyte-specific genes. Therefore, study of the balance between negative and positive regulators of adipogenesis is essential for understanding the early mechanisms involved in the establishment of obesity.

Prostaglandins (PG) are lipid paracrine mediators that were shown to play opposite and sometimes conflicting actions on cultured adipocytes. Therefore, until the recent development of genetically engineered mice models, their physiological importance in adipose tissue homeostasis remained unclear. PGE~2~ and PGD~2~/PGJ~2~ were shown to promote adiposity in mice through inhibition of lipolysis and induction of adipogenesis, respectively ([@B9]--[@B11]). By contrast, PGF~2α~ is a potent inhibitor of adipocyte differentiation in vitro ([@B12]--[@B14]). PGF~2α~, via its PGF (FP) receptor, activates downstream signaling pathways involving mitogen-activated protein kinase and/or calcineurin. This leads to inhibition of expression or activity of the proadipogenic transcription factors peroxisome proliferator-activated receptor γ and CCAAT/enhancer-binding protein α ([@B12],[@B15],[@B16]). Although the molecular action of PGF~2α~ has been well-described in cell cultures, its role in adipose tissue homeostasis in vivo has not been elucidated so far as the PGF synthases (PGFS) responsible for its production were only recently identified.

Indeed, we showed that some aldo-keto reductase 1B (AKR1B) members exhibited PGFS activity in vitro. Human AKR1B1 and murine Akr1b3 and Akr1b7 catalyze the synthesis of PGF~2α~ from its precursor PGH~2~ through their 9,11-endoperoxide reductase activity ([@B17]). Although a recent study indicated that the PGFS activity of Akr1b3 can influence adipogenesis in 3T3-L1 cells ([@B18]), no defect in adipose tissue homeostasis was reported in Akr1b3-deficient mice ([@B19]). Contrasting with the ubiquitous Akr1b3 protein, Akr1b7 isoform is expressed in a restricted set of tissues (i.e., adrenal glands, reproductive organs, and intestine) ([@B20]--[@B23]) and was found more recently in the adipose tissue ([@B24]). Interestingly, in fat depots, Akr1b7 expression is limited to the preadipocyte-enriched stromal fraction and downregulated during the differentiation into adipocytes ([@B24]). Consistently, overexpression of Akr1b7 in 3T3-L1 preadipocytes inhibits their differentiation, whereas Akr1b7 knockdown accelerates the adipogenic program. All of these data show that Akr1b7 exerts an antiadipogenic action in cell culture, although the mechanisms involved and the potential role of its PGFS activity remain to be established. We recently demonstrated that Akr1b7 is able to regulate the stress-induced response of adrenal gland by generating a PGF~2α~ signal in vivo ([@B25]). Hence, we hypothesized that the enrichment of Akr1b7 in the adipose stromal fraction could have a key role in preventing adiposity in vivo by controlling PGF~2α~ content. To firmly demonstrate the antiadipogenic action of Akr1b7 and the possible involvement of PGF~2α~ in this process, we generated *Akr1b7*^−/−^ mice and characterized their phenotype under standard or obesogenic diet conditions. We report that ablation of Akr1b7 increases adiposity under regular diet and decreases metabolic rate. This predisposes mice to develop severe obesity under a high-fat diet (HFD). These phenotypes result from deregulation of both adipogenesis and lipogenesis through a PGF~2α~-dependent mechanism.

RESEARCH DESIGN AND METHODS {#s1}
===========================

Generation of *Akr1b7*-null mice. {#s2}
---------------------------------

*Akr1b7* genomic vector was created using PCR-amplified fragments from a phage λ genomic clone containing the whole *Akr1b7* gene. The targeted construct was generated by inserting hygromycine resistance cassette flanked by two loxP sites and a third loxP to flank exons 4--6 ([Fig. 1*A*](#F1){ref-type="fig"}). The 11-kb targeting fragment was linearized and electroporated into 129/Sv embryonic stem cells. Hygromycine-resistant clones were screened for homologous recombination by Southern blot of *Hin*dIII-digested DNA with the 5′ untranslated region probe of the *Akr1b7* gene. Chimeric males, obtained by microinjecting positive clones into C57BL/6J blastocysts, were crossed with 129/Sv wild-type (WT) females to screen for germline transmission. Homozygous animals for *Akr1b7^flox-hygro^* allele were crossed with mice of the MeuCre40 transgenic line ([@B26]) to obtain recombination between loxP1 and loxP3 sites. Mosaic animals containing the *Akr1b7*-null allele lacking exons 4--6 were detected by Southern blotting. They were crossed with 129/Sv WT animals to generate *Akr1b7*^+/−^ mice. Details on vector construction or genotyping are available on request. *Akr1b7*^−/−^ mice were born viable at Mendelian frequency and showed no defects in reproductive functions as reported for a previous model of *Akr1b7* knockout (KO) mice ([@B27]).

![Generation of *Akr1b7* KO mice. *A*: Genomic organization of the *Akr1b7* WT allele (*top*). *Akr1b7* exons are represented by black boxes. The 5′ probe used for the genotyping analyses is indicated by a gray bar. Genomic organization of the *Akr1b7* recombined allele (or triloxP conditional allele *Akr1b7^flox-hygro^*) after homologous recombination of the targeting construct (*middle*). Genomic organization of the *Akr1b7*-null allele obtained after breeding of *Akr1b7^flox-hygro^* homozygous females with MeuCre40 males ([@B26]) (*bottom*). Homologous recombination of the targeting construct and Cre-mediated recombination events between loxP1 and loxP3 sites, generating an *Akr1b7*-null allele, were screened by Southern blotting. *B*: Southern blot analysis of the homologous recombination of the targeting construct. The 5′ probe revealed an 11-kb *Hin*dIII (H in *A*) fragment corresponding to the WT allele and a 9.3-kb *Hin*dIII fragment corresponding to the recombined allele (*Akr1b7^flox-hygro^*). *Lanes 2*and *3*: WT mice (^+/+^). *Lanes 1*and*4*: heterozygous floxed mice (lox/+). *C*: Southern blot analysis for the *Akr1b7*-null allele. After Cre-mediated loxP recombination, mosaic animals containing the *Akr1b7*-null allele were crossed with WT animals to generate *Akr1b7*^+/−^ mice. The 5′ probe revealed a 7.7-kb *Hin*dIII fragment corresponding to the null allele. *Lanes 2*and*3*: WT mice (^+/+^). *Lanes 1*and*4*: *Akr1b7*^+/−^ mice (+/−). *D*: Western blot analysis of Akr1b isoforms expression in different tissues from *Akr1b7^+/+^* (WT) and *Akr1b7*^−/−^ (KO) mice. gon., gonadal; peri-ad., periadrenal.](2796fig1){#F1}

Mice, diet, and treatments. {#s3}
---------------------------

All animal studies were approved by the Auvergne Ethics committee and conducted in agreement with international standards for animal welfare. WT and mutant littermate (KO) males were fed ad libitum a standard diet (Harlan Diet) or a high-fat diet (HFD) (63% kcal fat, 19% kcal carbohydrate, and 18% protein) (U8954, Safe) for either 12 or 5 weeks, respectively. Food intake was measured daily over a 6-day period. For phenotypic rescue studies, *Akr1b7*-null mice were intraperitoneally injected daily with vehicle PBS or cloprostenol (0.1 μg/g/day; Sigma-Aldrich) throughout the duration of HFD protocols. Mice were killed by decapitation, and truncal blood was collected.

**Ambulatory activity**. {#s4}
------------------------

Ambulatory activity of 3-, 9-, and 18-month-old mice was recorded with the Activiwheel software (IntelliBio). Mice were housed individually in cages containing an activity wheel (IntelliBio). The recordings of locomotor activity were performed at least on six mice of each genotype. Two recordings of 24 h were performed per mouse.

Indirect calorimetry. {#s5}
---------------------

Respiratory gas exchanges were measured continuously using whole-body calorimetric chambers (TSE Systems, Bad Homburg v.d.h., Germany). Energy expenditure was calculated using Weir's equation ([@B28]). Respiratory quotient was calculated from the ratio between CO~2~ production and O~2~ consumption.

Culture of 3T3-L1 cells. {#s6}
------------------------

3T3-L1 preadipocytes were induced to differentiate as previously described ([@B24]).

**Gene expression**. {#s7}
--------------------

RNAs were isolated from mouse tissues or 3T3-L1 cells using TRIzol reagent (Invitrogen), and cDNAs were synthesized with M-MLV reverse transcriptase (Promega). Gene expression was assessed by real-time quantitative PCR (RTqPCR) using TaqMan probes and PCR Mastermix (Applied Biosystems) or SYBR green and standard primers ([Supplementary Table 1](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-1297/-/DC1)). Each reaction was performed in triplicate, quantification was performed by the ΔΔCt method, and relative gene expression was normalized to peptidylprolyl isomerase B levels (ppib). The following TaqMan probes were used: *Scd1* Mm01197142_m1; *Fasn* Mm01253292_m1; *Acaca* Mm01304257_m1; *Akr1b3* Mm01135578_g1; and *Ppib* Mm00478295_m1.

Plasma and intratissular metabolites. {#s8}
-------------------------------------

Blood samples were collected after an overnight fasting. Insulin/leptin and adiponectin/resistin (Thermo Fisher Scientific) levels were measured by ELISA kits (BioVendor, Assaypro; both Thermo Fisher Scientific). Plasma concentration of cholesterol, triglycerides (Thermo Fisher Scientific), glycerol, and free fatty acids (Randox) were determined using commercial kits. For intratissular lipids assays, lipids were extracted from livers as previously described ([@B29]).

Histology and in vivo bromodeoxyuridine labeling studies. {#s9}
---------------------------------------------------------

WAT were fixed in 4% paraformaldehyde and embedded in paraffin. Sections (7 μm) were stained with hematoxylin/eosin and images captured for determination of cell surface with ImageJ software (National Institutes of Health). Livers were fixed in 4% paraformaldehyde and cryoprotected in sucrose overnight before −80°C OCT freezing. The 10-μm cryosections were performed at −16°C before Oil Red O staining.

Bromodeoxyuridine (BrdU) was administered to 16-week-old mice by intraperitoneal injection (50 mg/kg) every second day of the last 3 weeks of the 5-week HFD protocol. BrdU labeling was detected on WAT paraffin sections. Deparaffinized sections were incubated 25 min at 95°C in unmasking solution (sodium citrate buffer 10 mmol/L, pH 6, Tween 0.05%) before incubation with 1:50 dilution of mouse anti-BrdU antibody (Roche) revealed by goat anti-mouse Alexa 555 at 1:1000 (Molecular Probes). Sections were then incubated with Hoechst (Sigma-Aldrich), mounted in PBS-glycerol, and photographed on Zeiss LSM 510 Meta Confocal microscope (Carl Zeiss).

Immunoblotting. {#s10}
---------------

Proteins (20--40 μg) were loaded on SDS-PAGE, transferred onto nitrocellulose, and detected with the following antibodies: rabbit anti-Akr1b7 (L4; 1:5,000), rabbit anti-Akr1b3 (L5; 1:2,000), rabbit anti-Akr1b8 (L7; 1:2,000) ([@B25]), rabbit anti-Akt (Cell Signaling Technology; 1:1,000), rabbit anti--*p*-Akt ser473 (Epitomics; 1:3,000), rabbit anti-FP receptor (Cayman Chemical; 1:500), mouse anti--Srebp-1 (Thermo Scientific; 1:200), rabbit anti--β-actin (Sigma-Aldrich; 1:5,000), or mouse anti--β-tubulin (Sigma-Aldrich; 1:1,000).

Glucose and insulin tolerance tests. {#s11}
------------------------------------

These tests were performed on 14- and 5-h fasted mice, respectively. Blood glucose concentration was measured from the tail vein at 0, 15, 30, 60, 90, and 120 min after intraperitoneal injection of glucose (2 g/kg body weight) or insulin (0.75 units/kg body weight) (Novo Nordisk).

Insulin signaling. {#s12}
------------------

Mice were placed in conditions of insulin tolerance test. WAT, liver, and muscle were collected 10 min after insulin injection. Insulin-stimulated phosphorylation of Akt on Ser473 was analyzed by immunoblotting. Signals were quantified with Quantity One software (Bio-Rad).

Quantification of PGs in WAT. {#s13}
-----------------------------

Quantification of PGF~2α~, PGE~2~, and PGD~2~ was performed on WAT from 5-week-old mice. Deuterated standards (10 ng of d4-PGF~2α,~ d4-PGE~2~, and d4-PGD~2~ from Cayman Chemical) were added to homogenized tissue samples. Extraction and derivatization to obtain products of interest were performed as previously described ([@B25]). Quantification was performed after analysis of unlabeled and deuterated PGs by gas chromatography--mass spectrometry (Agilent Technologies).

Statistical analysis. {#s14}
---------------------

Results are expressed as means ± SD. Statistical significance of differences between experimental groups was assessed using tests specified in figure legends.

RESULTS {#s15}
=======

Generation of *Akr1b7*^−/−^ mice. {#s16}
---------------------------------

The strategy to generate *Akr1b7*^−/−^ mice is depicted in [Fig. 1*A--C*](#F1){ref-type="fig"}. In WT mice, Akr1b7 was strongly detected in the adrenal gland and to a lesser extent in WAT. In contrast, it was undetectable in brown adipose tissue (BAT), muscle, or liver ([Fig. 1*D*](#F1){ref-type="fig"}). Absence of Akr1b7 signal in KO tissues confirmed complete inactivation of the *Akr1b7* gene. Mouse also expresses two other members of Akr1b family, Akr1b3 and Akr1b8, but their expression pattern in adipose tissue has never been characterized. Using specific antibodies ([@B25]), we showed that Akr1b3 was expressed in all tissues tested, whereas Akr1b8 was absent from all adipose depots and muscle but abundant in adrenal and liver. Importantly, accumulation of both Akr1b3 and Akr1b8 isoforms was not upregulated in *Akr1b7*^−/−^ tissues.

Akr1b7 ablation results in increased adipogenesis and lipogenesis. {#s17}
------------------------------------------------------------------

Under standard diet, *Akr1b7*^−/−^ mice gained weight faster than WT mice starting at 7 to 8 weeks. This difference was exacerbated with time ([Fig. 2*A*](#F2){ref-type="fig"}). Six-month-old *Akr1b7*^−/−^ mice exhibited a significant excess of major WAT depots, such as gonadal, peri-adrenal, and inguinal WAT ([Fig. 2*B*](#F2){ref-type="fig"}) and an increased liver mass. In contrast, weight of other organs including heart, kidney, and testis was not affected. Therefore, lack of Akr1b7 led to a significant overweight, correlated with expansion of WAT. This was confirmed by higher plasma leptin levels in KO mice ([Table 1](#T1){ref-type="table"}). In contrast, there was no alteration of adiponectin or resistin levels ([Table 1](#T1){ref-type="table"}).

![Akr1b7 ablation leads to an excess of adipose tissue. *A*: Body weight of WT and *Akr1b7*^−/−^ mice (KO) fed with a standard diet (*n* = 10--12/genotype). \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001 using two-way ANOVA and Bonferroni posttest. *B*: Relative weight of major adipose tissue depots and other organs as a percentage of body weight from 6-month-old KO and WT mice (*n* = 6 to 7/group). *C*: Representative pictures showing microscopic hematoxylin/eosin-stained sections of gonadal adipose tissue (*top panel*) and area of adipocytes measured from paraffin sections of major adipose depots from 6-month-old KO and WT mice (*bottom panel*) (*n* = 4/group). *D*: *Scd1* is upregulated in WAT of *Akr1b7* null mice. *Scd1*, *Fasn*,*Acc1*, and *Srebp-1c* (lipogenesis) and *Dgat1*, *Dgat2*, and *Gpat* (triglyceride synthesis) gene expression were analyzed by RTqPCR on mRNAs from WAT of 6-month-old *Akr1b7* KO and WT mice. Bars represent the mean relative quantification (KO versus WT) of at least seven individual mice ± SD. *E*: Total DNA content in perigonadal and inguinal white fat pads from 6-month-old KO and WT mice (*n* = 7/group). gon., gonadal; ing, inguinal; peri-ad., periadrenal. \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.005, §*P* = 0.07 using Student *t* test. (A high-quality color representation of this figure is available in the online issue.)](2796fig2){#F2}

###### 

Plasma parameters of 24-week-old WT and *Akr1b7*-null mice

![](2796tbl1)

Measurement of cross-sectional areas of adipocytes revealed clear adipocyte hypertrophy in all *Akr1b7*^−/−^ white adipose depots compared with WT ([Fig. 2*C*](#F2){ref-type="fig"}). In agreement with this observation, mRNA levels of the lipogenic genes *Scd1*and *Fasn* were found increased in mutant gonadal WAT ([Fig. 2*D*](#F2){ref-type="fig"}), suggesting enhancement of the lipogenic capacity, although no change was recorded for expression of *Srebp-1c* and genes related to triglyceride synthesis. In addition, the DNA content of the fat depots was significantly higher in *Akr1b7*^−/−^ than in WT mice, demonstrating increased cellularity ([Fig. 2*E*](#F2){ref-type="fig"}). Altogether, these results suggest that under standard diet, deletion of *Akr1b7* leads to expansion of adipose tissue, which may be the result of improvement of both lipid storage, leading to adipocyte hypertrophy and adipogenesis, which leads to adipocyte hyperplasia.

The increased adiposity of *Akr1b7*^−/−^ mice relative to their WT counterparts was not attributable to differences in food consumption and ambulatory activity. Indirect calorimetry revealed that *Akr1b7*^−/−^ mice exhibited decreased energy expenditure (1.510 ± 0.055 vs. 1.358 ± 0.025 kJ/24 h/g) and respiratory exchange ratio (0.91 ± 0.02 vs. 0.86 ± 0.02) ([Supplementary Fig. 1](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-1297/-/DC1)). These data indicate that *Akr1b7*^−/−^ mice have a lower metabolic rate and a switch to relatively more fat oxidation.

Lack of Akr1b7 predisposes to diet-induced obesity. {#s18}
---------------------------------------------------

To test whether lack of *Akr1b7* gene could predispose to diet-induced obesity, we fed 5-week-old WT and KO mice with an HFD for 12 weeks and monitored growth. In contrast with WT HFD mice, *Akr1b7*^−/−^HFD mice gained weight rapidly and became obese. This was associated with a fivefold increase in plasma leptin levels and reduced food intake ([Fig. 3](#F3){ref-type="fig"}). The exacerbated obese phenotype observed in *Akr1b7*^−/−^ mice fed with an HFD compared with regular diet was accompanied by a marked increase in plasma levels of triglycerides, glycerol, and free fatty acids, which remained unchanged under a standard diet ([Tables 1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}). We concluded that lack of Akr1b7 predisposed mice to develop severe obesity on an HFD.

![*Akr1b7*^−/−^ mice are more sensitive to diet-induced obesity. *A*: Body weight gain of WT and *Akr1b7*^−/−^ mice fed with HFD. \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001 using two-way ANOVA and Bonferroni posttest. *B*: Plasma leptin levels of 17-week-old WT and *Akr1b7*^−/−^ mice fed with HFD. *C*: Food intake measured at 16 weeks of age every day over a 6-day period during HFD. *n* = 6 to 7/group for each experiment. \**P* \< 0.05 using Student *t* test.](2796fig3){#F3}

###### 

Plasma parameters of 17-week-old WT and *Akr1b7*-null mice fed with a high-fat diet for 12 weeks

![](2796tbl2)

*Akr1b7*^−/−^ mice display liver steatosis and progressive insulin resistance. {#s19}
------------------------------------------------------------------------------

Oil Red O staining and triglycerides assays revealed that *Akr1b7*^−/−^ liver accumulated a large amount of lipid droplets and contained twice as many triglycerides than WT ([Supplementary Fig. 2*A*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-1297/-/DC1)), confirming that *Akr1b7*^−/−^ mice fed with a standard diet developed liver steatosis from 6 months of age.

To determine the respective roles of WAT lipolysis and liver lipogenesis in steatosis, plasmatic pools of lipids were measured, and mRNAs of genes involved in lipid and glucose metabolism were quantified in the liver. Compared with WT mice, *Akr1b7*^−/−^ mice showed unchanged fasted plasma levels of free fatty acids and glycerol ([Table 1](#T1){ref-type="table"}), suggesting that lack of Akr1b7 did not increase basal WAT lipolysis. In contrast, the significant increase in *Scd1* expression in the liver of KO mice was correlated to the presence of steatosis ([Supplementary Fig. 2*B*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-1297/-/DC1)). However, this link remains unclear because expression of upstream lipogenic genes and triglyceride synthesis genes was unchanged. Finally, mRNA expression of genes related to β-oxidation and gluconeogenesis was unaltered in mutant mice.

Excess of adipose tissue and liver steatosis are frequently associated with altered glucose homeostasis and insulin resistance. Although fasting plasma glucose tended to be more elevated in 6-month-old *Akr1b7*^−/−^ than in WT mice ([Fig. 4*A*](#F4){ref-type="fig"}, *right*), both exhibited similar responses to the glucose tolerance test ([Fig. 4*A*](#F4){ref-type="fig"}, *left*). However, *Akr1b7*^−/−^ mice showed an attenuated response to insulin during the insulin tolerance test ([Fig. 4*B*](#F4){ref-type="fig"}, *left*). The absence of significant fasted hyperglycemia in *Akr1b7*^−/−^ mice along with basal hyperinsulinemia ([Fig. 4*B*](#F4){ref-type="fig"}, *right*) suggest a resistance to the insulin-mediated action on hepatic glucose output.

![Lack of Akr1b7 leads to insulin resistance. *A*and *B*: *Left*, glucose tolerance test (GTT) and insulin tolerance test (ITT). Six-month-old WT and *Akr1b7* null mice (*n* = 7/group) were either fasted for 16 h before receiving an intraperitoneal injection of 2 g/kg glucose or 5 h before receiving an intraperitoneal injection of 0.75 units/kg insulin. Blood glucose concentration was measured at the indicated time points. *Right*, fasting plasma glucose and insulin levels of the WT and *Akr1b7* KO mice fasted overnight. *C*: *Right*, Western blot analysis of phospho-Akt (P-Akt) at Ser473 and total Akt levels in WAT, liver, and muscle of 3- (*top*), 6- (*middle*), and 9-month-old (*bottom*) WT and *Akr1b7* KO mice after insulin injection. *Left*, quantifications of insulin-induced Akt Ser473 phosphorylation reported to total Akt levels in WT and *Akr1b7* KO mice normalized with β-actin signal. \**P* \< 0.05, \*\**P* \< 0.005 using Student *t* test.](2796fig4){#F4}

To examine time-dependent changes in insulin sensitivity, we quantified Akt phosphorylation on Ser473 in response to insulin surge in peripheral tissues of 3-, 6-, and 9-month-old mutant and WT mice. Insulin-induced Akt phosphorylation remained unchanged in muscle, liver, or WAT of 3-month-old *Akr1b7*^−/−^ mice ([Fig. 4*C*](#F4){ref-type="fig"}) in agreement with their normal response to the insulin tolerance test (not shown). In contrast, insulin-dependent Ser473 phosphorylation was reduced by 42% in liver from mutant mice of 6 months of age, whereas both muscle and WAT retained normal insulin response. Finally, Akt phosphorylation was reduced by at least 40% in all three tissues from 9-month-old mutant mice ([Fig. 4*C*](#F4){ref-type="fig"}). Thus, whole-body insulin resistance observed in mutant mice of 6 months of age is at least linked to a defect in insulin-induced Akt phosphorylation in liver. In these mice, unaffected insulin responsiveness in other peripheral tissues implies normal muscle (and WAT) glucose disposal and likely explains the unaffected postchallenge glucose levels ([Fig. 4*A*](#F4){ref-type="fig"}). Importantly, progressive insulin resistance of *Akr1b7*^−/−^ mice occurs from the age of 6 months secondarily to establishment of the overweight phenotype.

Expansion of *Akr1b7*^−/−^ adipose tissue is linked to decreased PGF~2α~ levels. {#s20}
--------------------------------------------------------------------------------

Our observations suggest that Akr1b7 is acting on adipose tissue by regulating both adipocyte differentiation and lipogenesis. We previously showed that Akr1b7 is endowed with a PGFS activity both in vitro and in living cells ([@B17],[@B25]). When we compared the levels of various PGs in adipose tissue from *Akr1b7*^−/−^ and WT mice ([Fig. 5*A*](#F5){ref-type="fig"}), we found that PGF~2α~ contents were specifically reduced by 45% in Akr1b7-deficient adipose tissue, whereas PGE~2~ and PGD~2~ were unaltered. Importantly, these changes occurred without any alteration in *Akr1b3* gene expression ([Fig. 5*B*](#F5){ref-type="fig"}), which has been reported to affect adipocyte differentiation in vitro ([@B18]). We next examined expression of the receptors for PGF~2α~ (FP~A~ and FP~B~) in various mouse tissues and found that adipose depots were major sites of FP protein expression ([Fig. 5*C*](#F5){ref-type="fig"}).

![Decreased levels of PGF~2α~ in *Akr1b7*^−/−^ adipose tissue. *A*: PG contents measured by mass spectrometry of adipose tissue from 5-week-old WT and *Akr1b7* KO mice. *B*: Relative mRNA levels of *Akr1b3* in WAT of WT and KO mice (*n* = 6/group). *C*: Western blot analysis of FP receptor isoforms expression in different tissues from WT mice. gon., gonadal; ing., inguinal; peri-ad., periadrenal. \**P* \< 0.05 using Student *t* test.](2796fig5){#F5}

To confirm that the alteration of adipose tissue homeostasis resulted from decreased PGF~2α~ production, 4-week-old *Akr1b7*^−/−^ mice were treated daily for 3 months with cloprostenol, a synthetic PGF~2α~. Plasma leptin levels of *Akr1b7*^−/−^ mice were significantly decreased by cloprostenol ([Fig. 6*A*](#F6){ref-type="fig"}), reflecting a reduction of WAT mass. Indeed, compared with *Akr1b7*^−/−^ control mice, mice injected with cloprostenol showed a significant reduction in adipocyte areas and lower *Scd1* gene expression in gonadal WAT ([Fig. 6*B* and *C*](#F6){ref-type="fig"}). Hence, in good agreement with the PGFS activity of Akr1b7, cloprostenol treatment was able to correct increased adiposity observed in Akr1b7-deficient mice.

![Phenotypic rescue by injection of PGF~2α~ agonist. *A--C*: *Akr1b7*-null mice were daily injected with 0.1 μg/g body weight of cloprostenol, a PGF~2α~ agonist, or with vehicle from 4--16 weeks of age (*n* = 7--9/group). *A*: Fasted plasma leptin levels from vehicle WT and KO mice and from KO mice treated with cloprostenol (KO + clopro.); statistical significance was assessed by Mann--Whitney test. *B*: Representation of adipocyte proportion according to their size. Adipocyte area was measured on paraffin sections from *Akr1b7* KO mice treated with vehicle (KO) or with cloprostenol (KO + clopro.). *C*: Expression of lipogenic genes *Scd1* and *Fasn* in adipose tissue from *Akr1b7* KO mice treated with vehicle (KO) or with cloprostenol (KO + cloprostenol) analyzed by RTqPCR. *D*: RTqPCR of lipogenic genes *Scd1*, *Fasn*, *Acc1*, and *Srebp-1c*(*left*) and Western blot analysis of Srebp-1 precursor and mature cleaved forms in 3T3-L1 adipocytes (*right*). Differentiated adipocytes were treated 24 h with various concentrations of cloprostenol or with vehicle. *E*and*F*: Cloprostenol effect on adipose tissue expansion induced by 5-week HFD in *Akr1b7* KO mice. *E*: Weight of gonadal WAT from WT mice, KO mice, and KO mice treated with cloprostenol (KO+clopro) after standard diet (SD) or HFD. *F*: Detection of new adipocyte production in vivo by BrdU labeling. Confocal immunofluorescence analysis was performed on paraffin section taken from WT and KO animals exposed to BrdU over the last 3 weeks of the 5-week HFD with or without cloprostenol treatment. Nuclei were stained using Hoechst, and autofluorescence from the green channel was used to detect tissue structures. Quantification of BrdU-positive adipocyte-associated nuclei was carried out from *n* = \>900 nuclei/group (*n* = 4/group). \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.005 using Student *t* test. (A high-quality digital representation of this figure is available in the online issue.)](2796fig6){#F6}

Our in vivo data ([Figs. 2*C--E*](#F2){ref-type="fig"} and [6*A--C*](#F6){ref-type="fig"}) showed that lack of Akr1b7, by lowering PGF~2α~levels, led to hypertrophy of adipocytes in which high levels of FP receptors were detected ([Fig. 5*C*](#F5){ref-type="fig"}). To test a direct impact of PGF~2α~ on lipogenesis, we treated 3T3-L1 adipocytes with various concentrations of cloprostenol. Cloprostenol reduced mRNA levels of *Scd1* and *Fasn* genes in a dose-dependent manner, whereas neither *Srebp-1c* transcripts nor mature protein levels were affected ([Fig. 6*D*](#F6){ref-type="fig"}). This result demonstrated that in addition to inhibiting adipocyte differentiation, PGF~2α~ could also repress lipogenic genes in mature adipocytes in an Srebp-1c--independent manner.

To test the possibility that expansion of WAT in *Akr1b7*^−/−^ mice could also be the result of an improved recruitment of new adipocytes, mice were exposed to HFD for 5 weeks in the presence or absence of cloprostenol and treated with BrdU for the last 3 weeks. In agreement with the sensitivity of Akr1b7-deficient WAT to expand in response to long-term HFD ([Fig. 3](#F3){ref-type="fig"}), a 5-week exposure to HFD was sufficient to impart a 7.7-fold increase of gonadal WAT mass in *Akr1b7*^−/−^ mice compared with the 1.7-fold increase observed in WT mice ([Fig. 6*E*](#F6){ref-type="fig"}). Concomitant cloprostenol treatment eventually reduced the expansion of mutant WAT mass to values similar to those of mutant mice fed with a standard diet. Quantification of new adipocyte production during HFD exposure revealed a 3.5-fold increase in BrdU-positive adipocyte-associated nuclei in gonadal WAT from *Akr1b7*^−/−^ compared with WT mice ([Fig. 6*F*](#F6){ref-type="fig"}). Cloprostenol treatment of *Akr1b7*^−/−^ mice reduced production of new adipocytes during HFD-induced adipose tissue expansion to values similar to those of WT mice fed with HFD. Altogether, these data supported in vivo evidence that the PGFS activity of Akr1b7 regulates adipose tissue expansion by repressing both adipocyte hypertrophy and adipocyte recruitment.

DISCUSSION {#s21}
==========

Akr1b7 has antiadipogenic and antilipogenic activities. {#s22}
-------------------------------------------------------

We investigated the physiological function of Akr1b7, a protein enriched in stromal vascular fraction of WAT, by generating a KO mouse model. Our results showed for the first time the direct contribution of a protein producing the antiadipogenic paracrine factor PGF~2α~ in the regulation of adipose tissue expansion. Indeed, even under standard diet, *Akr1b7*^−/−^ mice exhibited an increased number and size of white adipose cells. This increased adiposity was correlated with a specific decrease in PGF~2α~ concentrations in WAT. The ability of chronic administration of a PGF~2α~ agonist to reverse the adipose phenotype of *Akr1b7*^−/−^ mice shows that antiadipogenic activity of Akr1b7 is essentially resulting from its PGFS activity.

This is the first demonstration that PGF~2α~ is indeed an antiadipogenic molecule in vivo. Moreover, we showed that the antiadipogenic function of PGF~2α~was not only resulting from inhibition of the recruitment of preadipocytes but also from inhibition of adipocyte lipogenesis in *Akr1b7*^−/−^ mice. This direct effect of PGF~2α~ on lipogenesis was confirmed in 3T3-L1 adipocytes.

*Akr1b7*^−/−^ mice showed exacerbated sensitivity to obesity in a 129/Sv genetic background. This phenotype is associated with metabolic disorders such as hepatosteatosis and insulin resistance even under standard diet. Therefore, *Akr1b7*^−/−^ mouse is a powerful model to study obesity and its complications.

The phenotype of *Akr1b7*^−/−^ mice is linked to Akr1b7 function in adipose tissue. {#s23}
-----------------------------------------------------------------------------------

In the adrenal cortex, *Akr1b7* expression was shown to limit glucocorticoids release under stress conditions through an internal-feedback loop ([@B25]). Glucocorticoids are powerful regulators of adipose tissue homeostasis ([@B30]). Nevertheless, we showed that basal plasma corticosterone levels were not affected in *Akr1b7*^−/−^ mice ([Table 1](#T1){ref-type="table"}). This excludes an adrenal contribution to the adipose phenotype.

In the intestine, *Akr1b7* expression is regulated by several nuclear receptors and is mainly implicated in detoxification processes by metabolizing bile acids or lipid peroxidation products ([@B23],[@B31],[@B32]). This function could influence nutrient intake and disrupt energy balance. However, we did not find any alterations of food consumption, fecal production, or fat content ([Supplementary Fig. 1](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-1297/-/DC1)) and intestine histology (not shown) in *Akr1b7*^−/−^ mice. Therefore, it seems unlikely that lack of Akr1b7 in the intestine could account for increased adiposity in *Akr1b7*^−/−^ mice.

*Akr1b14* mRNA, the rat ortholog of *Akr1b7*, is undetectable in the liver until induction by growth hormone or oxidative stress ([@B33],[@B34]). In mouse, *Akr1b7* expression is hardly detected in the liver under basal conditions ([@B21]) but is inducible by farnesoid X receptor/pregnane X receptor agonists ([@B31],[@B32]). Recently, it was shown that forced overexpression of Akr1b7 in the liver using adenoviral vector significantly lowered hepatic lipid contents in genetically obese mice, suggesting a protective effect against hepatosteatosis ([@B35]). Hence, we cannot completely exclude that hepatosteatosis observed in *Akr1b7*^−/−^ mice could also result from the chronic lack of a very faint hepatic expression of the enzyme. However, several arguments suggest that this metabolic complication is rather the consequence of altered adipose tissue physiology in *Akr1b7*-null mice. First, using our antibody designed to discriminate Akr1b isoforms ([@B25],[@B36]), we never managed to detect Akr1b7 in WT mouse liver ([Fig. 1*D*](#F1){ref-type="fig"}). Second, we demonstrated that hepatosteatosis and insulin resistance were established from the age of 6 months, far after the increase of adiposity in *Akr1b7*^−/−^ mice. Finally, it is well-established that excessive development of adipose tissue can lead to hepatosteatosis and insulin resistance through several interconnected pathways ([@B37]). Thus, the overall phenotype of *Akr1b7*^−/−^ mice can mainly be attributed to Akr1b7 function in the adipose tissue.

*Akr1b7*-null mice phenotype does not rely on defects in detoxification of lipid peroxidation by-products. {#s24}
----------------------------------------------------------------------------------------------------------

Besides its PGF~2α~ synthase activity, Akr1b7 has other reported enzymatic activities with possible impacts on adipose tissue, such as reduction of 4-hydroxynonenal (4-HNE) ([@B17],[@B25],[@B38]). Increased 4-HNE levels in response to oxidative stress promote and perpetuate the obese state ([@B39]) and can be involved in the development of insulin resistance ([@B40],[@B41]). Oxidative stress in human and murine adipose tissue as well as in 3T3-L1 adipocytes affects the secretion of adipokines such as adiponectin and proinflammatory cytokines ([@B1],[@B41],[@B42]). However, *Akr1b7*^−/−^ mice showed no change in adiponectin levels ([Table 1](#T1){ref-type="table"}) and no significant increase of macrophage infiltration before the age of 6 months ([Supplementary Fig. 3](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-1297/-/DC1)). This indicates that excess adiposity of *Akr1b7*^−/−^ mice preceded elevation of inflammatory status. Moreover, we observed similar amounts of 4-HNE--protein adducts in liver, muscle, and adipose tissue from WT and mutant mice ([Supplementary Fig. 4](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-1297/-/DC1)). These results indicate that increased adiposity and insulin resistance in mutant mice is not linked to alteration of intracellular 4-HNE detoxification.

Akr1b7-dependent production of PGF~2α~ regulates adipose tissue homeostasis. {#s25}
----------------------------------------------------------------------------

For decades, PGF~2α~ has been implicated in the inhibition of adipogenesis ([@B12]--[@B14]), but its function on adipocyte differentiation was never established in vivo or tested on already differentiated tissues. We demonstrate in this study that a decrease in intra-adipose tissue PGF~2α~ levels following Akr1b7 ablation leads to increased adiposity. This phenotype results from alleviation of the repression exerted on both adipocyte precursors recruitment and on lipid storage in mature adipocytes and can be reverted by exogenous PGF~2α~ injections. Using 3T3-L1 adipocytes, we confirmed that PGF~2α~ inhibited expression of lipogenic enzymes. This unsuspected result is consistent with the high expression of the FP receptor in cultured adipocytes ([@B18]) and in vivo ([Fig. 5*C*](#F5){ref-type="fig"}). The mechanism leading to PGF~2α~-mediated inhibition of lipogenic genes remains to be explored. We showed in this paper that it occurs independently of Srebp-1c, in agreement with previous findings indicating that Srebp-1c does not transactivate lipogenic genes in adipocytes ([@B43]).

Akr1b family members: novel actors in adipose tissue homeostasis? {#s26}
-----------------------------------------------------------------

In mouse, aldose reductases Akr1b3 and Akr1b7 are so far the only members of the Akr1b family that are expressed in adipose tissue ([Fig. 1*D*](#F1){ref-type="fig"}). A recent study indicated that PGFS activity of Akr1b3 could influence adipogenesis. Indeed, siRNA-mediated Akr1b3 knockdown decreased the concentrations of PGF~2α~ in 3T3-L1 medium, which resulted in enhanced adipogenesis ([@B18]). The presence of Akr1b3 could thus account for maintenance of a low level of PGF~2α~ in the adipose tissue of *Akr1b7*^−/−^ mice ([Fig. 5*A*](#F5){ref-type="fig"}). However, this isoform was not able to compensate for the lack of Akr1b7. Moreover, no defect in adipose tissue homeostasis was reported in *Akr1b3*^−/−^ mice but careful in vivo investigations will be needed to definitively conclude ([@B19]).

Among human members of the AKR family, AKR1B1 and AKR1C3 exhibited a PG synthase activity in vitro. AKR1C3 is expressed in human adipocytes and was for a long time considered as the only PGFS in humans ([@B44],[@B45]). However, AKR1B1 was recently shown to have a higher PGFS activity than AKR1C3 in vitro ([@B17]) and to be highly active in human endometrium ([@B46]). The role of AKR1B1 has been extensively studied in the pathogenesis of diabetes complications ([@B47]), but its role in the physiology of adipose tissue is an almost virgin field of investigation. One could hypothesize that AKR1B1 could act as an antiadipogenic factor through local PGF~2α~ production.

In conclusion, our mouse model provides functional evidence for novel mechanisms linking prostanoid metabolism with adipose tissue homeostasis. It also opens up new perspectives on the potential contribution of AKR1B isoforms to physiological control of adipose tissue expansion and pathogenesis of obesity in patients.

This article contains Supplementary Data online at <http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-1297/-/DC1>.
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